Stifel Maintains Buy on Insmed, Raises Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $39 to $67.
May 31, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Stephen Willey maintains a Buy rating on Insmed and raises the price target from $39 to $67.
The raised price target from $39 to $67 by a reputable analyst suggests strong confidence in Insmed's future performance, likely leading to positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100